Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support the in vivo persistence of regulatory T cells - PubMed
8 hours ago
- #IL-2 Therapy
- #Immunocytokine
- #Regulatory T Cells
- Miniaturized version of F5111 immunocytokine (miniF5111 IC) was created by fusing IL-2 to a single-chain variable fragment (scFv) of the F5111 antibody.
- Binding and signaling studies showed miniF5111 IC selectively targets regulatory T cells (Tregs) over effector lymphocytes, similar to the full-length version.
- In vivo, miniF5111 IC expanded Tregs but had a reduced serum half-life compared to the full-length F5111 IC.
- Engineered Tregs expressing miniF5111 IC demonstrated prolonged persistence and sustained FOXP3 expression after adoptive transfer.
- The miniaturized immunocytokine is a promising platform for targeted immune cell activation, with therapeutic potential in autoimmune diseases and transplant rejection.